ERA-NET on Cardiovascular Diseases

Joint Transnational Call for Proposals 2020 (JTC2020):

“Prevention of Vascular Cognitive Impairment through Early Detection of Cardiovascular Diseases”

Submission deadline for proposals: April 2nd 2020 at 17:00 (CET)

Electronic proposal submission system: https://ptoutline.eu/app/era-cvd_jtc2020

For further information, please visit us on the website www.ERA-CVD.eu

or

contact the Joint Call Secretariat (JCS2020):

Clara Martin
Phone: +34 91 822 2567
Email: c.martin@isciii.es

Ignacio Baanante
Phone: +34 91 822 2576
Email: ibaanante@isciii.es
Content

1. RATIONALE................................................................................................................................. 3
2. PARTICIPATING FUNDING AGENCIES......................................................................................... 3
3. AIM OF THE CALL .......................................................................................................................... 4
4. SCOPE OF THE CALL ..................................................................................................................... 4
5. CALL IMPLEMENTATION BOARDS ............................................................................................... 6
6. APPLICANTS.................................................................................................................................... 6
7. EVALUATION.................................................................................................................................... 9
8. FINANCIAL AND LEGAL ISSUES.................................................................................................. 12
9. REPORTING AND DISSEMINATION............................................................................................... 14
10. CONTACT AND FURTHER INFORMATION ............................................................................... 15
11. TABLES ....................................................................................................................................... 17
Table I. Contact information of the national/regional research funding organisations participating in ERA-CVD JTC2020 ........................................................................................................ 17
Table II. Eligibility of beneficiary institutions and indicative funding commitment for the funding organisations participating in ERA-CVD JTC2020 .............................................................. 19
1. **RATIONALE**

It is estimated that 55 million deaths occurred in the world in 2017, of which 17.7 million were from cardiovascular disease\(^1\). Each year, cardiovascular diseases (CVD) cause 3.9 million deaths in the European continent and over 1.8 million deaths in the European Union (EU). Furthermore, these diseases are one of the leading causes of long-term sickness, chronic conditions and labour force loss due to disability, and thus pose a major health- and socio-economic problem in Europe and beyond. Based on a better understanding of the causes of CVD, the development of new diagnostic markers, innovative therapies and the improvement in medical technologies requires innovative research based on scientific excellence. Cardiovascular research and its translation into better preventive, diagnostic and therapeutic outcomes are fundamental for patients in Europe and worldwide.

The ERA-NET on Cardiovascular Diseases (ERA-CVD) was established under the ERA-NET scheme of the European Commission ([http://www.ERA-CVD.eu](http://www.ERA-CVD.eu)). The aim of ERA-CVD is to foster new, as well as extend existing, transnational cooperation of European countries, and to coordinate research efforts and funding programmes of its partner countries.

Under the umbrella of ERA-CVD, the fifth joint transnational call 2020 (JTC2020) is now launched to promote transnational research projects focusing on "**Prevention of Vascular Cognitive Impairment through Early Detection of Cardiovascular Diseases**".

2. **PARTICIPATING FUNDING AGENCIES**

The following funding organisations have agreed to fund this joint call for multinational research projects. The call will be conducted simultaneously by the funding organisations in their respective countries and coordinated by the Joint Call Secretariat (JCS; ISCIII, Spain). The proposals must be submitted to the JCS centrally as described in chapter 6.

- Belgium, Research Foundation Flanders (FWO)
- Belgium, Fund for Scientific Research - FNRS (F.R.S.-FNRS)
- Canada, Canadian Institutes of Health Research (CIHR)
- Estonia, Estonian Research Council (ETAg)
- France, French National Research Agency (ANR)

\(^1\) GBD 2017 Causes of Death Collaborators. Lancet. 2018; 392: 1736-1788
3. **AIM OF THE CALL**

The ERA-CVD funding organizations are seeking multi-disciplinary and translational research proposals. The individual components of joint applications should be complementary and contain novel and ambitious ideas to answer key questions or lead to a step-wise change in understanding of CVDs. There should be a clear added value in funding the collaboration over individual projects by sharing of resources (e.g., models, databases, diagnostics, etc.), harmonisation of data, sharing of specific know-how and/or innovative technologies. The consortia should be based on complementarities and sharing of expertise, with a clear translational research approach.

It is known that CVD can cause cognitive decline and that risk factors for CVD such as (but not limited to) age, gender, family history, smoking, high blood pressure, diabetes, obesity, sleep deprivation, sedentary behaviour, and others are also associated with vascular cognitive impairment (VCI)². VCI refers to the contribution of vascular pathology to any severity of cognitive impairment, ranging from subjective cognitive decline and mild cognitive impairment to dementia. The social, human and economic burden associated with the incidence of CVD and associated cognitive decline is high and increasing. Based on the current evidence, early CVD interventions are needed in order to prevent VCI.

4. **SCOPE OF THE CALL**

The call topic is based on mutual agreement between the ERA-CVD partners. The aim of the call is to enable scientists from different countries to come together and build effective collaborations on the early detection of CVD for the prevention of VCI.

---

Research should focus on the association between vascular and cardiac precipitating or causative factors, and the molecular effectors to prevent the onset of VCI. Projects should have a clear translational research approach with a potential clinical impact.

Research proposals submitted to this call should address one of the following sub-themes:

- Interdisciplinary approaches (e.g., integrating biomedicine, physics, chemistry, mathematics or systems biology) to explore pathophysiological processes (e.g., microcirculation), develop applications for diagnosis, or new therapeutic approaches.
- Research on sex or gender differences, co-morbidities or in segmented populations, in order to give further mechanistic insights into the development and progression of VCI, to identify novel risk/protective factors and differences in treatment responses.

No funding will be provided for already existing studies.

Multi-disciplinary and translational research proposals that combine basic and clinical approaches are encouraged. Proposals must clearly demonstrate the potential scientific impact as well as the added-value of transnational collaboration: sharing of expertise and resources (e.g., models, databases, diagnostics, etc.), harmonization of data, access to innovative technologies, etc.

Consortia are encouraged to demonstrate engagement with industry (especially Small and Medium Size Enterprises – SMEs) for its active participation including sharing of resources, capabilities, and expertise for transfer of pre-clinical results into clinical utility. Likewise, patient organizations are invited to participate where appropriate. **Note: Some funders do not fund these private parties. To learn about the specific national/regional regulations with regard to researchers from private parties consult the Guidelines for Applicants, ANNEX 2: National/regional regulations.**

The following types of research projects **are excluded from the call**:

- Interventional clinical trials.
- Building up of new cohorts, registries and/or biomaterial banks.
- Conducting screenings.
- Proposals mainly focused on Alzheimer disease (or any other neurodegenerative disease).
5. CALL IMPLEMENTATION BOARDS

With the support of the JCS, the Call Steering Committee (CSC) and the Scientific Evaluation Board (SEB) will manage the evaluation process and the final selection and awarding of research projects.

The CSC is composed of a single representative from each national/regional funding organisation participating in ERA-CVD JTC2020. The CSC will supervise the preparation and the implementation of the call and will make all decisions concerning the call. Based on the ranking list delivered by the SEB and on the available funding, the CSC will recommend to the national/regional funding organisations the projects to be funded. Based on these recommendations, final decisions will be made by the national/regional funding organisations.

A panel of internationally recognised scientific experts will perform the evaluation of the submitted proposals. The SEB, as well as external peer reviewers, will be responsible for the evaluation of the proposals. The SEB will be constituted by a fraction of the group of reviewers involved in the remote evaluation step. Both the SEB members and external reviewers will sign declarations on conflicts of interest and confidentiality. SEB and CSC members are not allowed to submit or participate in proposals within this call.

6. APPLICANTS

Funding Recipients/Eligibility

Joint research proposals may be submitted by applicants belonging to one of the following categories depending on national/regional eligibility rules as specified in Annex 2 of the “Guidelines for applicants”:

- Academic research teams (from universities or other higher education or research institutions).
- Clinical/public health sector research teams (from hospitals/public health and/or other health care settings and health organisations).
- Enterprise’s research teams. Participation of small and medium-size enterprises (SMEs) or industry is encouraged if allowed by national/regional regulations.

Note: Inclusion of a non-eligible applicant in a proposal may lead to the rejection of the entire proposal without further review. The individual research groups in the successful applicant consortia will be funded by the funding organisation of their country/region that is participating in the
ERA-CVD JTC2020. The applications are therefore subject to the eligibility criteria of national/regional funding organisations. The adherence to the national/regional regulations is mandatory. Applicants should refer to Annex 2 of the “Guidelines for applicants” for the national/regional eligibility criteria and regulations, and should contact their respective national/regional funding organisation for additional clarification.

**Note:** An eligibility check before the proposal submission is mandatory for the Ministry of Health – Italy (MoH-IT).

Only applications from multinational research consortia will be considered. Each consortium should have the critical mass to achieve ambitious scientific goals and should clearly demonstrate added value of the collaborative work between the individual partners.

Only projects that fulfil the legal and ethical international/EU, national and institutional standards will be funded. All procedures involving human beings have to conform to the Helsinki Declaration.

**Each consortium submitting a proposal must involve a minimum of three (3) to a maximum of five (5) eligible partners.** Additionally, eligible partners must come from at least three (3) different countries participating in the call (see list above). A consortium must not involve more than one partner from the same country or region participating in the call, unless the second partner is an associated partner who secures their own funding. As an exception, two (2) applicants from Spain may be comprised in the same research consortium. For Belgium, two (2) applicants per consortium are also allowed; however, participation is limited to one applicant per region/community. This in practice comes down to one applicant per participating Belgian funding agency per consortium.

In order to strengthen the European research area in the field of CVDs, a wide inclusion of researchers from all the countries/regions participating in the call is encouraged, with a particular attention to research teams from Estonia, Latvia, Poland, Slovakia and Turkey. Research consortia including teams from these countries may increase the total number of eligible partners to six (6).

A consortium may include one (1) partner not eligible to the national/regional funding organisations participating in this call or from countries not involved in this call only if this group provides
a demonstrable added-value to the consortium. Such a partner is not considered within the minimum number of three eligible (3) partners mentioned above. Upon submission of proposal, this partner must prove that funding for its activities in the project is already secured.

Overall, a research consortium can comprise a maximum of seven (7) partners, if including at least one (1) partner from the above indicated countries (Estonia, Latvia, Poland, Slovakia and Turkey) and one (1) partner with own funding along with the maximum of five (5) eligible partners.

Each research consortium must nominate a project coordinator, from the consortium applicants eligible to receive funding. The project coordinator will represent the consortium externally and to the JCS and CSC, and will be responsible for the scientific management of the project (such as controlling, reporting, intellectual property rights issues, etc.). Each project will be represented by a single PI (the Project Coordinator), who will be the contact person for the respective national/regional funding organisation.

The duration of the projects can be up to three (3) years. However, applicants can receive funding for less than three (3) years according to eligibility criteria and regulations of the funding organizations participating in the ERA-CVD JTC2020.

**Submission of joint proposals**

ERA-CVD will be implemented through a one-stage submission procedure. Proposals must be written in English and must be submitted to the JCS by the project coordinator through the electronic submission system “PT-Outline”; [https://ptoutline.eu/app/era-cvd_jtc2020](https://ptoutline.eu/app/era-cvd_jtc2020).

In preparing the proposals, applicants should strictly follow the rules described in this call text and in the “Guidelines for Applicants”, and use the application forms available from the ERA-CVD website ([www.ERA-CVD.eu](http://www.ERA-CVD.eu)).

Applicants should take note of individual national/regional rules, and contact their national/regional contact points for specific questions. The proposals must be submitted to the electronic submission system no later than **April 2, 2020 at 17:00 (CET)**. The final decision will be communicated to all the (successful and unsuccessful) coordinators in October 2020.

**Eligibility check**

The JCS will perform an eligibility check of the proposals to ensure that they meet the call’s formal criteria (e.g., date of submission; number of participating countries; inclusion of all necessary
information in English). Proposals that do not meet the formal criteria will be rejected at this stage. The JCS will then forward the proposals to the national funding organisations, which will perform a formal eligibility check of compliance with their respective regulations. Proposals that meet the eligibility criteria will enter the evaluation process.

Proposals are only eligible to apply if they fulfil the legal and ethical international/EU, national and institutional requirements, as well as FAIR principles\(^3\) and preclinical quality assurance, if applicable. Assistance for provision of the information on the project description can be found in the general ARRIVE\(^4\) guidelines.

7. EVALUATION

7.1 Evaluation criteria

Proposals will be assessed according to the following evaluation criteria.

1. **Excellence**
   a) Clarity and relevance of the objectives
   b) Credibility of the proposed approach and methodology
   c) Soundness of the concept
   d) Innovative potential
   e) Competence and experience of participating research partners in the field(s) of the proposal (previous work in the field, specific technical expertise)

2. **Impact**
   a) Potential of the expected results for future clinical, public health and/or other socio-economic health relevant applications including patients' needs
   b) Added-value of transnational collaboration: gathering a critical mass of patients/biological material, sharing of resources (models, databases, diagnosis etc.), harmonization of data, sharing of specific know-how and/or innovative technologies, etc.
   c) Effectiveness of the proposed measures to exploit and disseminate the project results (including management of intellectual property rights [IPR]), to communicate the project, and to manage research data where relevant

---

\(^3\) FAIR: Findable, Accessible, Interoperable, Reusable (for more information; see “The FAIR Guiding Principles for scientific data management and stewardship” [https://www.nature.com/articles/sdata201618](https://www.nature.com/articles/sdata201618))

\(^4\) The ARRIVE Guidelines: Animal Research: Reporting of In Vivo Experiments. Originally published in PLOS Biology, June 2010
d) Industry and Patient Organization participation/engagement (when appropriate/applicable)

3. Quality and efficiency of the implementation
   a) Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks and resources and time-frame
   b) Complementarity of the participants within the consortium
   c) Appropriateness of the management structures and procedures, including risk and innovation management
   d) Budget and cost-effectiveness of the project (rational distribution of resources in relation to project’s activities, partner’s responsibilities and time-frame)
   e) Sub-criteria 2a and 2b will be prioritized for assessing the impact of proposals

Scoring

Range and interpretation of the scores

A scoring system from 0 to 5 will be used to evaluate the proposal's performance with respect to each of the three evaluation criteria, as follows:

0: Failure. The proposal fails to address the criterion in question, or cannot be judged because of missing of incomplete information.

1: Poor. The proposal shows serious weaknesses in relation to the criterion in question.

2: Fair. The proposal generally addresses the criterion, but there are significant weaknesses.

3: Good. The proposal addresses the criterion in question well but improvements are necessary.

4: Very good. The proposal addresses the criterion very well but small improvements are possible.

5: Excellent. The proposal successfully addresses all aspects of the criterion in question.

Thresholds

Evaluation scores will be awarded for the 3 main criteria, and not singularly for the different aspects listed below the criteria. Each criterion will be scored out of 5. The threshold for individual criteria will be 3. The overall threshold, applying to the sum of the three individual scores, will be 12. The maximum sum of scores from all three criteria is 15 points.
In the evaluation of proposed research projects, special attention will be reserved for potential ethical issues (e.g., research on humans, animals or biomaterials including stem cells). Only projects that fulfil the legal and ethical International, EU, National and Institutional regulations and standards are eligible for funding.

It is a contractual obligation of ERA-CVD partners to ensure the confidentiality of information and documents obtained during the evaluation and the selection procedures of the joint transnational call.

**Evaluation by SEB**

Each proposal will be allocated to at least three (3) SEB members. One of the SEB members will be appointed as rapporteur. The SEB members and the external remote reviewers will independently assess the proposals according to the evaluation criteria mentioned above.

**Rebuttal**

Each proposal coordinator is provided with the opportunity of studying the assessments and commenting on the arguments and evaluations of the reviewers, which remain anonymous. This stage allows applicants to comment on factual errors or misunderstandings that may have been committed by the referees while assessing their proposal and to reply to reviewers’ questions. However, issues which are not related with reviewers’ comments or questions cannot be addressed and the work plan cannot be modified at this stage.

**Ranking of the proposals**

In preparation of the SEB panel meeting, all SEB members will get access to the assigned reports and to the optional responses submitted by the coordinators following the rebuttal stage. During the SEB panel face-to-face meeting, each proposal will be presented by the rapporteur and discussed by the SEB members on the basis of the individual evaluation reports and rebuttals so as to reach consensus scoring. As a result of these discussions and as an outcome of the SEB meeting, a ranking list of the proposals will be established.
Funding decision

Based on the ranking list established by the SEB, the CSC will decide on the projects to be suggested for funding by the national/regional funding organisations.

If necessary, the CSC will determine a priority order for proposals, which have been awarded the same score within the ranking list. The following approach will be applied successively for every group of *ex aequo* proposals requiring prioritisation, starting with the highest scored group, and continuing with the participation of countries not yet funding any proposals.

The JCS will communicate to all project coordinators the final decision on the approval for funding of the respective proposal together with the final evaluation report from the SEB.

8. FINANCIAL AND LEGAL ISSUES

Funding details

Each country/region funds only its national/regional component of the transnational research project. Eligible costs and funding rates may vary according to the regulations of the individual national/regional funding organisation. Prior to submitting a proposal, applicants should verify the funding rules of the respective national/regional funding organisation (see Annex 2 of the “Guidelines for applicants”) and are recommended to ask for clarification to the corresponding contact person (see national/regional contact details in Annex I).

The coordinators might be asked to present the results of their projects at an intermediate and/or a final ERA-CVD symposium. The project proposal budget should account for expenses for the participation of coordinators and/or national/regional research partners to an intermediate and/or a final ERA-CVD symposium. The budget should also consider travel expenses for young scientists (PhD students, postdocs, Early Career Scientists) involved in the proposal and willing to join young scientist activities organized by ERA-CVD. It is recommended to check the national/regional funding regulations on costs eligibility with the respective national/regional funding organisations. Funding is granted for a maximum of three years according to national/regional regulations.
**Funding contracts**

In principle, changes within the composition of the research consortia or in the budget are not allowed. Overall, they should be “subject to the terms and conditions of relevant funding organisations”.

Depending on the time needed for the administration of granting funds to the respective national/regional research groups, individual projects of a research consortium are expected to start by April/May 2021. The official start date shall be communicated by the project coordinator to the JCS and shall appear in the consortium agreement established in accordance to section 6.3 below.

**Research consortium agreement, ownership of intellectual property rights, ethical issues, data management plan**

The members of a funded research project consortium must sign a Consortium Agreement (CA). While the consortium members are strongly encouraged to sign this CA before the official project start date the CA has to be signed no later than six months after the project start date. Please note that national/regional regulations may apply concerning the requirement for a CA. The consortium members are strongly advised to check the country/region-specific information in the “Guidelines for applicants” and/or to contact the respective national/regional contact point. Upon request, the CA must be made available to the concerned ERA-CVD JTC2020 funding organisations.

The results of the research project and IPR created should be actively exploited and made available for use, whether for commercial purpose or not, in order for public benefit to be obtained from the knowledge created funded by public funds.

The ERA-CVD JTC2020 funding organisations shall have the right to use documents, information and results submitted by the research partners and/or to use the information and results for their own purposes, provided that the owners’ rights are kept and their origin is specified.

Any ethical issues should be addressed at the proposal submission stage, and subsequent authorization presented at the latest and upon request by the national/regional funding organisations, before the process of grant negotiation.
Each successful consortium will have to provide a Data Management Plan (DMP) according to international state-of-the-art standards (FAIR\textsuperscript{5} and GDPR\textsuperscript{6} compliant and secure) as an integral part of the project. The data management plan should address criteria such as data accessibility, format and storage, stewardship/curation, timeline and schedule for the submission date, quality of metadata, and data security. The DMP must be submitted to the JCS no later than six months after the official project start date. For this, it may helpful to check the data management plan template at the CVD website well beforehand. The DMPs are living documents and can be modified during the course of the project, generally alongside annual reporting. Upon termination of the projects (after three years) the DMPs will be published on ERA-CVD websites according to scientific transparency and 'open science'. Where nationally relevant, a format for data storage, data/model exchange and data/model sharing agreements will be available in due time to successful consortia by the national funder.

Confidentiality of proposals

Proposals and any related information shall be kept confidential by the SEB members, the external reviewers and the CSC members. Proposals shall not be used for any purpose other than the evaluation and subsequent monitoring of the funded projects. Proposals shall include a publishable summary, which will clearly identify the main goals of the project. All other project details shall remain strictly confidential.

9. REPORTING AND DISSEMINATION

The project coordinators of all the funded projects must submit annual scientific project reports (annual report to be submitted within two months after the end of each year; the reference date being the common project start date stated in the Consortium Agreement) and a final scientific project report (submitted within two months of the end of the project) to the JCS JTC2020. All reports must be written in English and comply with the annual or final reporting templates that will be provided to the coordinators of the funded projects. In addition, the reports will include a monitoring questionnaire to be used to assess the achievements of the funded projects. The research partners are jointly responsible for delivery of the reports, and only reports delivered on behalf of the consortium, via the project coordinator, will be accepted.

In addition to these centrally-administered ERA-CVD JTC2020 reports, principal investigators may be requested to submit financial and/or scientific reports to their national/regional funding organisations, according to national/regional regulations.

The progress and final results of each individual contract/letter of grant will be monitored by the respective national/regional funding organisations. In case of serious difficulties in the conduct of the research project, the coordinator shall promptly inform the JCS and the relevant funding organisations. These funding organisations will decide upon the proper actions to be taken. The coordinators and/or national/regional research partners will be asked to present the results of their projects at an intermediate and/or a final ERA-CVD symposium.

Furthermore, funding recipients are asked to provide information about their funded project to the project database CardioScape (www.cardioscape.eu). A CardioScape representative will provide details about the information needed.

ERA-CVD follows an open-access policy. Funded research partners must consider open access publication of their results. For communication purposes, coordinators of the funded projects are required to submit periodic concise lay term summaries of the projects. The first summary is required upon receipt of funding decision and needs to include a lay term summary and appropriate figures.

Funding recipients must ensure that all outcomes (publications, etc.) arising from the transnational project include a proper acknowledgement that the project is supported by the respective national/regional funding organisations and, collectively, by the national funding organisations under the framework of the ERA-NET ERA-CVD initiative.

10. CONTACT AND FURTHER INFORMATION

The JCS is set up at ISCIII, Spain. The JCS will assist the CSC and the national/regional funding organisations during the implementation of the call.

The JCS JTC2020 ISCIII will be responsible for the follow-up phase until the funded research projects have ended. The JCS will be responsible for the administrative management of the call evaluation. It will be the primary contact referring to the ERA-CVD JTC2020 procedures towards the research consortia, the funding organisations (CSC) and the peer reviewers (SEB members
and external experts). The project coordinator will be the person contacted by the JCS during the application procedure, and must forward this information to the other participants.

Further information on ERA-CVD, the ERA-CVD JTC2020 and its planned schedule is available on the ERA-CVD website: www.ERA-CVD.eu. Before submitting a proposal, applicants are strongly advised to contact their national/regional funding organisations for national/regional specific regulations (see contact details in Annex I).
# 11. TABLES

<table>
<thead>
<tr>
<th>Country/Region</th>
<th>Participating organisation</th>
<th>National/Regional contact point</th>
</tr>
</thead>
</table>
| Belgium        | Research Foundation Flanders (FWO) | Alain Deleener  
Phone: +32 2 550 15 95  
Toon Monbaliu  
Phone: +32 2 550 15 70  
Email: eranet@fwo.be |
| Belgium        | Fund for Scientific Research - FNRS (F.R.S.-FNRS) | Joël Groeneveld  
Phone: +32 2504 9270  
Email: joel.groeneveld@frs-fnrs.be |
| Canada         | Canadian Institutes of Health Research (CIHR) | Bryan Lemire  
Phone: 1-613-952-5728  
Email: Bryan.Lemire@cihr-irsc.gc.ca  
Ryan Perry  
Phone: 1-780-492-5748  
Email: rjperry@ualberta.ca |
| Estonia        | Estonian Research Council (ETAg) | Katrin Kello  
Phone: +372 731 7361  
Email: katrin.kello@etag.ee |
| France         | French National Research Agency (ANR) | Deborah Zyss  
Phone: +33 1 73 54 81 74  
Email: Deborah.ZYSS@agencerecherche.fr |
| Israel         | Chief Scientist Office of the Ministry of Health (CSO/MOH) | Irit Allon  
Phone: +972 (0)2 5082167  
Email: irit.allon@moh.health.gov.il |
| Italy          | Italian Ministry of Health (MoH-IT) | Maria Grazia Mancini  
Phone: +39.06.5994.3215  
Email: mg.mancini-esterno@sanita.it  
research.EU.dgric@sanita.it |
| Latvia         | State Education Development Agency (VIAA) | Uldis Berkis  
Phone: +371-29472349  
Email: Uldis.Berkis@viaa.gov.lv  
Maija Bundule  
Phone: +371 - 67785423  
Email: Maija.Bundule@viaa.gov.lv |
| Norway         | The Research Council of Norway (RCN) | Henrietta Blankson  
Phone: +47 922 33 762  
Email: hbl@rcn.no |
<table>
<thead>
<tr>
<th>Country</th>
<th>Organization</th>
<th>Contact Person</th>
<th>Phone</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poland</td>
<td>National Centre for Research and Development (NCBR)</td>
<td>Dominika Mickiewicz</td>
<td>+48 22 39 07 139</td>
<td><a href="mailto:dominika.mickiewicz@ncbr.gov.pl">dominika.mickiewicz@ncbr.gov.pl</a></td>
</tr>
<tr>
<td>Slovakia</td>
<td>Slovak Academy of Science (SAS)</td>
<td>Martin Novak</td>
<td>+421 5751 0119</td>
<td><a href="mailto:mnovak@up.upsav.sk">mnovak@up.upsav.sk</a></td>
</tr>
<tr>
<td>Spain</td>
<td>National Institute of Health Carlos III (ISCIII)</td>
<td>Clara Martín</td>
<td>+91 82 22567</td>
<td><a href="mailto:c.martin@isciii.es">c.martin@isciii.es</a></td>
</tr>
<tr>
<td>Taiwan</td>
<td>Ministry of Science and Technology (MoST)</td>
<td>Ching-Mei Tang</td>
<td>+886 2 2737 7557</td>
<td><a href="mailto:cmtom@most.gov.tw">cmtom@most.gov.tw</a></td>
</tr>
<tr>
<td>Turkey</td>
<td>The Scientific and Technological Research Council of Turkey (TUBITAK)</td>
<td>Recep Emrah ÇEVİK</td>
<td>+90 312 298 1214</td>
<td><a href="mailto:emrah.cevik@tubitak.gov.tr">emrah.cevik@tubitak.gov.tr</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. Övgü ÇELİKLER ÖZER</td>
<td>+90 312 298 1210</td>
<td><a href="mailto:ovgu.celikler@tubitak.gov.tr">ovgu.celikler@tubitak.gov.tr</a></td>
</tr>
</tbody>
</table>
Table II. Eligibility of beneficiary institutions and indicative funding commitment for the funding organisations participating in ERA-CVD JTC2020

Consult the Guidelines for Applicants, ANNEX 2 for a detailed description of the eligibility of your National/regional funding organisation!

<table>
<thead>
<tr>
<th>Funding organisation</th>
<th>Country / Region</th>
<th>Funding applicants from academic entities</th>
<th>Funding applicants from clinical/public entities</th>
<th>Funding private entities</th>
<th>Envisaged funding commitment (M€ for 3 years)</th>
<th>Envisaged number of research projects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Foundation Flanders (FWO)</td>
<td>Belgium</td>
<td>YES</td>
<td>YES(^7)</td>
<td>NO</td>
<td>0.2 M€</td>
<td>1</td>
</tr>
<tr>
<td>Fund for Scientific Research - FNRS (F.R.S.-FNRS)</td>
<td>Belgium</td>
<td>YES</td>
<td>YES(^8)</td>
<td>NO</td>
<td>0.2 M€</td>
<td>1</td>
</tr>
<tr>
<td>CIHR-ICRH</td>
<td>Canada</td>
<td>YES</td>
<td>YES</td>
<td>NO</td>
<td>0.6 MCAD</td>
<td>2</td>
</tr>
<tr>
<td>Estonian Research Council (ETAg)</td>
<td>Estonia</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>0.1 M€</td>
<td>1</td>
</tr>
<tr>
<td>French National Research Agency</td>
<td>France</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>1 M€</td>
<td>4-5</td>
</tr>
<tr>
<td>Chief Scientist Office of the Ministry of Health (CSO/MOH)</td>
<td>Israel</td>
<td>YES</td>
<td>YES</td>
<td>NO</td>
<td>0.3 M€</td>
<td>2</td>
</tr>
<tr>
<td>Ministry of Health (MoH)</td>
<td>Italy</td>
<td>NO</td>
<td>YES(^9)</td>
<td>NO</td>
<td>1.5 M€</td>
<td>5-6</td>
</tr>
<tr>
<td>State Education Development Agency (VIAA)</td>
<td>Latvia</td>
<td>YES(^10)</td>
<td>NO(^11)</td>
<td>YES(^12)</td>
<td>0.42 M€</td>
<td>2</td>
</tr>
<tr>
<td>The Research Council of Norway (RCN)</td>
<td>Norway</td>
<td>YES</td>
<td>YES</td>
<td>NO</td>
<td>0.5 M€</td>
<td>2</td>
</tr>
<tr>
<td>National Centre for Research and Development (NCBR)</td>
<td>Poland</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>0.6 M€</td>
<td>1-3</td>
</tr>
</tbody>
</table>

7 Academic hospitals under the umbrella of a Flemish university  
8 Academic hospitals under the umbrella of a French speaking Belgian university  
9 Only Scientific Institutes for Research, Hospitalization and Health Care (Istituti di Ricovero e Cura a Carattere Scientifico pubblici e privati, IRCCS) and Istituto Superiore di Sanità (ISS)  
10 Only institutions registered in registry of scientific institutions in Latvia  
11 Except cases when the clinical partner is a company (see private partners)  
12 Only companies (business enterprises) registered in Latvia and having main activity in Latvia
<table>
<thead>
<tr>
<th>National Institute of Health Carlos III (ISCIII)</th>
<th>Spain</th>
<th>YES</th>
<th>YES</th>
<th>NO</th>
<th>0.5 M€</th>
<th>3-5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ministry of Science and Technology (MoST)</td>
<td>Taiwan</td>
<td>YES</td>
<td>YES</td>
<td>NO</td>
<td>0.5 M€</td>
<td>3-4</td>
</tr>
<tr>
<td>The Scientific and Technological Research Council of Turkey (TÜBİTAK)</td>
<td>Turkey</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>0.3 M€</td>
<td>1-2</td>
</tr>
</tbody>
</table>

Consult the Guidelines for Applicants, ANNEX 2 for a detailed description of the eligibility of your National/regional funding organisation!